Form D · Biotechnology
Cleave Biosciences, Inc.
Burlingame, CA · CIK 0001682401
Offering snapshot reported Jun 18, 2019 · SEC filing
- Reported sold
- $12M Offering amount: $20.8M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 4, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 18, 2019 | Initial | $11,970,369 | No comparison | 11 | SEC filing |
| Aug 17, 2016 | Initial | $25,950,003 | No comparison | 13 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-342143
Source: Form D, filed Jun 18, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Amy Burroughs | Director, Executive |
| Carol Gallagher | Director |
| Dennis Henner | Director |
| Mark Rolfe | Executive |
| Jonathan Root | Director |
| Alfred Scheidegger | Director |
| Andrew Schwab | Director |
| Laura Shawver | Director |
| Lewis Shuster | Director |
| Timothy Smith | Executive |
| Peter Thompson | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
863 Mitten Road, Suite 104
Burlingame, CA, 94010
Burlingame, CA, 94010